Risk of oral cleft from topiramate exposure increases with dosage
Study highlights that the risk of oral clefts in infants born to mothers who took topiramate for epilepsy was higher than that for women who took topiramate for other indications.
Topiramate is known to increase the risk of oral clefts when taken by pregnant women with epilepsy. However, it is unknown if lower doses — such as those for bipolar disorder — confer the same risk.
Researchers studied data on 1,360,101 mother-infant pairs, including 2,425 pairs exposed to topiramate during the first trimester.
They found that the risk of oral clefts was 4.1 per 1,000 live births in the topiramate group compared with 1.1 per 1,000 live births in the unexposed group (relative risk 2.90).
Restricting the study to women with epilepsy, they found that the risk of oral clefts was 12.3 per 1,000 infants born to mothers who took topiramate (relative risk 8.30). By contrast, in women taking topiramate for other indications, such as bipolar disorder, the risk of oral clefts was 2.1 per 1,000 exposed infants (relative risk 1.45).
Reporting in Neurology (online, 27 December 2017), the researchers said the findings indicated that larger doses of topiramate taken for epilepsy may confer a higher risk of oral clefts.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204441
Recommended from Pharmaceutical Press
FASTtrack: Pharmaceutical Compounding and Dispensing helps the student compounder to understand the key dosage forms in extemporaneous dispensing.